Die Grafik zeigt die prognostizierten Quartalsgewinne (Bereinigter Gewinn pro Aktie, EPS) und die tatsächlich erzielten Gewinne (grün: Analystenschätzungen übertroffen, rot: Analystenschätzungen verfehlt) für den ausgewählten Zeitraum.
Umsatz (USD)
Schätzung
Umsatz
Die Grafik zeigt die prognostizierten Quartalsumsätze und die tatsächlich erzielten Umsätze (grün: Analystenschätzungen übertroffen, rot: Analystenschätzungen verfehlt) für den ausgewählten Zeitraum.
Güte der Analystenschätzungen – EPS (aktueller Zeitraum)
Quartal / Datum
EPS (USD)
Schätzung (USD)
Abweichung
Quartal / Datum
Umsatz (Mio USD)
Schätzung (Mio USD)
Abweichung
Revisionen der Gewinnschätzungen
EPS-Schätzungen für die Geschäftsjahre
2026, 2027, 2028.
Allspring Global Investments Holdings LLC grew its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 1,326.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 46,056 shares of the specialty pharmaceutical company's stock after purchasing an additional 42,827 shares during the period.
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Boston Trust Walden Corp decreased its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 4.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 424,569 shares of the specialty pharmaceutical company's stock after selling 18,554 shares during the quarter.
DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Jefferies London Global Healthcare Conference on Tuesday, November 17, 2026, at 8:00 a.m. ET Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026, at 8:00 a.m.
Four pharmaceutical and biotech stocks are seeing unusual options activity today, with Inovio Pharmaceuticals Inc (NASDAQ:INO), Aquestive Therapeutics Inc (NASDAQ:AQST), X4 Pharmaceuticals Inc (NASDAQ:XFOR), and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) all drawing elevated volume.
Jazz Pharmaceuticals NASDAQ: JAZZ reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology businesses offset product-specific pressures and continued investment in its pipeline.
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Portfolios
0
Zum Anlegen oder Bearbeiten von Portfolios müssen Sie sich anmelden oder einen Account erstellen.
Aktuelle Aktie in ein Portfolio speichern oder neues Portfolio anlegen: